Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review

被引:16
|
作者
Van Der Weijst, Lotte [1 ]
Lievens, Yolande [1 ]
Schrauwen, Wim [2 ]
Surmont, Veerle [3 ]
机构
[1] Ghent Univ Hosp, Dept Radiotherapy Oncol, Ghent, Belgium
[2] Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium
[3] Ghent Univ Hosp, Dept Thorac Oncol, Ghent, Belgium
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
关键词
quality of life; review-systematic; lung cancer; methodological quality; NSCLC; RANDOMIZED PHASE-III; DOCETAXEL PLUS CISPLATIN; COMPREHENSIVE GERIATRIC ASSESSMENT; PATIENT-REPORTED OUTCOMES; COMPARING PACLITAXEL POLIGLUMEX; GEFITINIB MAINTENANCE THERAPY; PLATINUM-BASED CHEMOTHERAPY; TREATED JAPANESE PATIENTS; SINGLE-AGENT GEMCITABINE; ELDERLY-PATIENTS;
D O I
10.3389/fonc.2019.00715
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The majority of lung cancer patients are diagnosed with advanced non-small cell lung cancer (NSCLC), the bulk of which receive palliative systemic treatment with the goal to provide effective symptom palliation and safeguard health-related quality of life (HRQoL). Advanced NSCLC trials with HRQoL endpoints face methodological constraints limiting interpretability. Objectives: We provide a comprehensive overview of recent clinical trials evaluating the impact of systemic therapies on HRQoL in advanced NSCLC, focusing on the methodological quality, with the ultimate goal to improve interpretation, comparison and reporting of HRQoL data. Methods: A systematic literature review was performed. Prospective studies published over the last decade evaluating the impact of systemic treatments on HRQoL in advanced NSCLC were included. Methodological quality of HRQoL reporting was assessed with the CONSORT-PRO extension. Results: Hundred-twelve manuscripts describing 85 trials met all criteria. No formal conclusion can be drawn regarding the impact on HRQoL of different treatments. We report an important variety in methodological quality in terms of definitions of HRQoL, missing data points, lack of standardization of analyzing and presenting HRQoL and no standard follow-up time. The quality of HRQoL data reporting varies substantially between studies but improves over time. Conclusion: This review shows that in the heterogeneous landscape of trials addressing HRQoL in advanced stage NSCLC. Methodology reporting remains generally poor. Adequate reporting of HRQoL outcome data is equally important to support clinical decision-making as to correctly inform health policy regarding direct approval and reimbursement of the new drugs and combinations that will come online.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Quality of Life Outcomes for FDA-Approved Agents in Advanced Non-Small Cell Lung Cancer
    Albaba, H.
    Bezjak, A.
    Leighl, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S666 - S666
  • [42] Chemotherapy In Advanced Non-Small Cell Lung Cancer: A Review
    Joshi, S. C.
    Pant, I
    Shukla, A. N.
    Khan, F. A.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2008, 2 (02) : 780 - 785
  • [43] Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature
    Desage, Anne-Laure
    Bouleftour, Wafa
    Tiffet, Olivier
    Fournel, Pierre
    Tissot, Claire
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4643 - 4665
  • [44] Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients
    Fiteni, Frederic
    Vernerey, Dewi
    Bonnetain, Franck
    Vaylet, Fabien
    Sennelart, Helene
    Tredaniel, Jean
    Moro-Sibilot, Denis
    Herman, Dominique
    Laize, Helene
    Masson, Philippe
    Derollez, Marc
    Clement-Duchene, Christelle
    Milleron, Bernard
    Morin, Franck
    Zalcman, Gerard
    Quoix, Elisabeth
    Westeel, Virginie
    EUROPEAN JOURNAL OF CANCER, 2016, 52 : 120 - 128
  • [45] Afatinib: A Review in Advanced Non-Small Cell Lung Cancer
    Keating, Gillian M.
    TARGETED ONCOLOGY, 2016, 11 (06) : 825 - 835
  • [46] Quality of life in patients with non-small cell lung cancer
    Sarac, Sanja
    Milic, Rade
    Vasiljevic, Mira
    Sarac, Momir
    VOJNOSANITETSKI PREGLED, 2017, 74 (07) : 625 - 632
  • [47] A systematic review of the use and validation of health-related quality of life instruments in older cancer patients
    Fitzsimmons, Deborah
    Gilbert, Jacqueline
    Howse, Frances
    Young, Teresa
    Arrarras, Juan-Ignacio
    Bredart, Anne
    Hawker, Sheila
    George, Steve
    Aapro, Matti
    Johnson, Colin D.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (01) : 19 - 32
  • [48] Gefitinib for advanced non-small cell lung cancer
    Sim, Esther H. A.
    Yang, Ian A.
    Wood-Baker, Richard
    Bowman, Rayleen V.
    Fong, Kwun M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (01):
  • [49] Chemotherapy of advanced non-small cell lung cancer in elderly patients
    Rossi, A
    Gridelli, C
    ANNALS OF ONCOLOGY, 2006, 17 : 58 - 60
  • [50] Chemotherapy for advanced non-small cell lung cancer in the elderly population
    Santos, Fabio N.
    de Castria, Tiago B.
    Cruz, Marcelo R. S.
    Riera, Rachel
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (10):